EMA: No biowaivers for NTIDs [Dissolution / BCS / IVIVC]

posted by Helmut Homepage – Vienna, Austria, 2020-07-15 21:08 (1541 d 00:59 ago) – Posting: # 21704
Views: 4,105

Hi dshah,

❝ We are working on a NTI drug with high variability for which different dissolution media is recommended by USFDA.

❝ For BE study as per USFDA- a fasting and fed study for highest strength is recommended.


Why don’t you simply tell us that the drug is rivaroxaban? :-D

❝ For EMA- A fed study on highest strength and a fasting study on another mid strength is concluded based on guideline.


Fine. Though there is no product-specific guidance for rivaroxaban publishd by the EMA, most people would consider it an NTID indeed. Following the logic of other NTID-guidances that would mean acceptance limits of 80.00–125.00% for Cmax and 90.00–111.11% for AUC. In rare cases the limits of Cmax have to narrowed as well. Up to you to provide a justification.

❝ For waiver request for other strength we need acceptable in vitro dissolution testing of all strengths.


Biowaivers for NTIDs are not acceptable. BE-Guideline APPENDIX III:

Applying for a BCS-based biowaiver is restricted to highly soluble drug substances with known human absorption and considered not to have a narrow therapeutic index.


Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,240 posts in 4,884 threads, 1,655 registered users;
79 visitors (0 registered, 79 guests [including 15 identified bots]).
Forum time: 22:07 CEST (Europe/Vienna)

The epistemological value of probability theory is based on the fact
that chance phenomena, considered collectively and on a grand scale,
create non-random regularity.    Andrey Kolmogorov

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5